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Energy metabolismChronically elevated glucocorticoid levels impair cognition and are pro-inflammatory in the brain.
Deficiency or inhibition of 11b-hydroxysteroid dehydrogenase type-1 (11b-HSD1), which converts inac-
tive into active glucocorticoids, protects against glucocorticoid-associated chronic stress- or age-related
cognitive impairment. Here, we hypothesised that 11b-HSD1 deficiency attenuates the brain cytokine
response to inflammation. Because inflammation is associated with altered energy metabolism, we also
examined the effects of 11b-HSD1 deficiency upon hippocampal energy metabolism.
Inflammation was induced in 11b-HSD1 deficient (Hsd11b1Del/Del) and C57BL/6 control mice by
intraperitoneal injection of lipopolysaccharide (LPS). LPS reduced circulating neutrophil and monocyte
numbers and increased plasma corticosterone levels equally in C57BL/6 and Hsd11b1Del/Del mice, suggest-
ing a similar peripheral inflammatory response. However, the induction of pro-inflammatory cytokine
mRNAs in the hippocampus was attenuated in Hsd11b1Del/Del mice. Principal component analysis of
mRNA expression revealed a distinct metabolic response to LPS in hippocampus of Hsd11b1Del/Del mice.
Expression of Pfkfb3 and Ldha, key contributors to the Warburg effect, showed greater induction in
Hsd11b1Del/Del mice. Consistent with increased glycolytic flux, levels of 3-phosphoglyceraldehyde and
dihydroxyacetone phosphate were reduced in hippocampus of LPS injected Hsd11b1Del/Del mice.
Expression of Sdha and Sdhb, encoding subunits of succinate dehydrogenase/complex II that determines
mitochondrial reserve respiratory capacity, was induced specifically in hippocampus of LPS injected
Hsd11b1Del/Del mice, together with increased levels of its product, fumarate.
These data suggest 11b-HSD1 deficiency attenuates the hippocampal pro-inflammatory response to
LPS, associated with increased capacity for aerobic glycolysis and mitochondrial ATP generation. This
may provide better metabolic support and be neuroprotective during systemic inflammation or aging.
 2017 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Although glucocorticoids exert powerful anti-inflammatory
effects, chronically elevated glucocorticoid levels are associated
with pro-inflammatory conditions in humans and rodents, includ-
ing cognitive impairment and hippocampal dysfunction (Lupien
et al., 1998; Starkman et al., 2001). Prior stress or elevated gluco-
corticoid levels, including during aging, potentiate the brain pro-
inflammatory cytokine response to bacterial lipopolysaccharide
(LPS) (Frank et al., 2010, 2012; Barrientos et al., 2015). Even a mod-
est increase in basal glucocorticoid levels in rodents is associated
with greater CNS accumulation of pro-inflammatory markersstemic
2 M. Verma et al. / Brain, Behavior, and Immunity xxx (2017) xxx–xxx(Perez-Nievas et al., 2007). In rodents, adrenalectomy combined
with fixed low dose glucocorticoid replacement from mid-life can
prevent the decline in cognitive function associated with age-
related elevation of glucocorticoid levels (Landfield et al., 1981).
11b-hydroxysteroid dehydrogenase type-1 (11b-HSD1)
increases intracellular glucocorticoid levels by regenerating active
glucocorticoids (predominantly cortisol in humans, corticosterone
in rats and mice) from intrinsically inert forms (cortisone and 11-
dehydrocorticosterone, respectively) (Chapman et al., 2013). 11b-
HSD1 deficient mice maintain normal circulating levels of corticos-
terone and have increased adrenal gland size, to compensate for
the lack of tissue reactivation of active glucocorticoids (Carter
et al., 2009). 11b-HSD1 mediates many of the adverse cognitive
and metabolic effects of circulating corticosterone or cortisol
excess (Chapman et al., 2013; Morgan et al., 2014; Yau et al.,
2015). 11b-HSD1-deficiency or inhibition is protective against
age and/or stress related cognitive decline in rodents (Sooy et al.,
2010; Yau et al., 2007, 2001, 2011; Mohler et al., 2011), associated
with reduced intra-hippocampal levels of corticosterone (Yau et al.,
2015, 2015). Conversely, transgenic over expression of 11b-HSD1
in the forebrain of mice advances age related cognitive impairment
(Holmes et al., 2010). However, the molecular mechanisms under-
lying the protective effects of 11b-HSD1-deficiency against the
adverse centrally mediated effects of glucocorticoids remain
unknown.
In the periphery, 11b-HSD1-deficiency alters intermediary
metabolism and cellular glucose uptake (Morton et al., 2001,
2004; Wamil et al., 2011). These effects are particularly marked
when circulating glucocorticoid levels are elevated (Morgan
et al., 2014). Glucocorticoids are well known to affect glucose uti-
lization in the CNS (Doyle et al., 1994; de Leon et al., 1997; Brunetti
et al., 1998). Moreover, recent evidence has highlighted the impor-
tance of a metabolic switch from oxidative respiration to aerobic
glycolysis in stress-related inflammation or the aging brain
(Currais, 2015). These findings suggest that 11b-HSD1 may alter
brain energy metabolism, especially when the hypothalamic–pitui
taryadrenal (HPA) axis is activated. 11b-HSD1 is widely expressed,
including in resident macrophages (Gilmour et al., 2006; Zhang
et al., 2017) and other immune cells, where its expression is
increased following cellular activation (Coutinho et al., 2016)
(reviewed in Chapman et al., 2013). In many tissues, 11b-HSD1 is
up-regulated at sites of inflammation (Bryndova et al., 2004;
Ergang et al., 2011), though it remains unchanged at others
(Dover et al., 2007). It is highly induced by IL-1 and TNFa, and by
glucocorticoids, but again, not in all cells and tissues (Escher
et al., 1997; Tomlinson et al., 2001; Cai et al., 2001; Cooper et al.,
2001; Sai et al., 2009, 2008) (reviewed in Chapman et al., 2013).
11b-HSD1 modulates the inflammatory response in a site and
context-specific manner, with either beneficial or adverse effects
upon the severity and resolution of inflammation (reviewed,
Chapman et al., 2013).
Here we have tested the hypothesis that deficiency in 11b-
HSD1 is protective against a central pro-inflammatory state
induced by peripheral administration of LPS, a potent inflamma-
tory stimulus and activator of the HPA axis (Silverman and
Sternberg, 2012). We also predicted that an attenuated pro-
inflammatory cytokine response in the brain would be associated
with altered brain energy metabolism. We therefore examined
expression of key enzymes known to contribute to aerobic glycol-
ysis (or the Warburg effect), enzymes involved in oxidative meta-
bolism and substrate transporters (glucose and lactate). We
focussed on the hippocampus because of a considerable body of
work implicating it as a key locus for the neuroprotective effects
of 11b-HSD1 deficiency/inhibition following stress or during aging
(Yau et al., 2015, 2007, 2011, 2015; Holmes et al., 2010;
Sarabdjitsingh et al., 2014). Bacterial LPS was used to induce peri-Please cite this article in press as: Verma, M., et al. 11b-hydroxysteroid dehy
inflammation. Brain Behav. Immun. (2017), https://doi.org/10.1016/j.bbi.2017.tonitis and acute systemic inflammation in global 11b-HSD1 defi-
cient mice (Hsd11b1Del/Del). Sickness behaviour, pro-inflammatory
response and the associated alteration in energy metabolising
pathways were investigated.2. Materials and methods
2.1. Animals
Animal studies were conducted in strict accordance with the UK
Home Office Animals (Scientific procedure) Act 1986, amended in
2012 to comply with the European Directive 2010/63/EU. Studies
were conducted with prior approval from the University of Edin-
burgh Animal Welfare and Ethical Review Body. Mice were group
housed in a controlled environment (25 C, 12 h:12 h light dark
cycle) and provided with standard chow diet and water ad libitum.
Mice homozygous for a null allele of Hsd11b1 (termed Del), here
referred to as Hsd11b1Del/Del, were generated by Cre-LoxP mediated
deletion of exon 3 of the Hsd11b1 gene. Briefly, Hsd11b1f/f mice,
homozygous for a ‘‘floxed” allele of Hsd11b1 in which exon 3 is
flanked by LoxP sites, were generated in a C57BL/6 genetic back-
ground by TaconicArtemis, Denmark. Hsd11b1f/f mice were crossed
with mice expressing Cre recombinase from the Hprt locus
(expressed in the germ line) (Tang et al., 2002) to create Hsd11b1+/
Del mice, with germ line disruption of Hsd11b1. Hsd11b1+/Del mice
were subsequently backcrossed to C57BL/6 for at least five gener-
ations before generating homozygous Hsd11b1Del/Del mice. Back-
ground strain characterisation of Hsd11b1Del/Del mice against a
panel of SNP markers covering all chromosomes confirmed that
Hsd11b1Del/Del mice show 99.93–100% similarity to the C57Bl/6 ref-
erence genome (Vandermosten et al., in press). Assays of 11b-HSD
enzyme activity confirmed that Hsd11b1Del/Del mice lack 11b-HSD
activity in all tissues tested: the brain, liver, adipose tissue, lung
and peritoneal cells (Supplementary Fig. 1).
Male mice, aged 10–20 weeks, were used in experiments. Mice
were euthanised by CO2 asphyxiation, unless stated otherwise.
Brains were removed and hippocampi dissected on wet ice, snap
frozen on dry ice (for RNA extraction) or in liquid nitrogen (for
metabolite measurement) and stored at 80 C until analysis.
Spleens were dissected and weighed.
2.2. Sickness behaviour assay
Burrowing activity was quantified to assess sickness behaviour
as described (Deacon, 2006; Deacon, 2012). Burrowing behaviour
is dependent upon an intact hippocampus and, to a lesser extent,
prefrontal cortex (Deacon et al., 2002; Deacon et al., 2003). Briefly,
150 g of food pellets were placed in a burrowing tube sealed at one
end (20 cm in length; 6.8 cm in diameter, with screws at one end at
an angle of 90 elevating the open end by 3 cm). The amount of
food pellets burrowed overnight (for habituation) or over a 2 h per-
iod (baseline or during an experiment) was calculated from the
weight of food pellets left in the burrowing tube at the end of
the assay. Baseline burrowing activity was measured over 2 peri-
ods of 2 h, 48 h apart. Representative burrowing activity in
C57BL/6 and Hsd11b1Del/Del mice is shown in Supplementary
Fig. 2, with no difference observed between genotypes.
2.3. LPS administration
Baseline sickness behaviour was assessed in C57BL/6 and
Hsd11b1Del/Del mice prior to pseudo-randomisation into experimen-
tal groups. C57BL/6 and Hsd11b1Del/Del mice were injected (intra-
peritoneal) with 100 mg/kg LPS (Sigma-Aldrich, Dorset, UK) or vehi-
cle (0.9% saline) between 7:00 h and 09:45 h. Mice were eutha-drogenase-1 deficiency alters brain energy metabolism in acute systemic
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lected for the measurement of plasma corticosterone, 11-
dehydrocorticosterone and circulating leukocytes. Sickness beha-
viour was assessed in the 2 h prior to kill. Tissues were collected
as described above.2.4. Flow cytometry
Quantification of circulating blood leukocytes was performed
by flow cytometry as described (Kipari et al., 2013). Briefly, 30 ml
of trunk blood was added to 30 ml of sodium citrate (3.9% w/v).
Red blood cells were lysed by addition of 0.5 ml of FACSTM lysis
buffer (BD Biosciences, Oxford, UK), according to the manufac-
turer’s protocol. Fluorescent conjugated antibodies (100 ng each,
in a total of 50 ml PBS) were added and incubated on ice for 25
min. The antibodies used were: CD45-PE (30-F11; Biolegend, UK),
CD11b-FITC (M1/70; Biolegend, UK), Ly-6C-APC (AL-21; BD Bio-
sciences, UK), Ly-6G-PB (1A8; Biolegend, UK). Cells were collected
by centrifugation, resuspended in 100 ml of neutral buffered 10%
formalin (Sigma-Aldrich, Dorset, UK) and analysed using a BD
LSR Fortessa cell analyser (BD Bioscience, Oxford, UK) with manual
compensation for each antibody. Supplementary Fig. 3 shows the
gating strategy used to identify different classes of leukocytes. Data
analysis was performed using FlowJo software v8.2 (TreeStar, USA).
To determine the absolute numbers of cells, 5  104 fluorescent
flow-check fluorospheres (Beckman and Coulter, UK) were added
to each sample prior to analysis. Forward and side scatter were
used to distinguish cell and fluorospheres populations and cell
numbers were calculated from the ratio of cells to fluorospheres
in each sample.2.5. Measurement of plasma steroids using LC-MS/MS
Plasma levels of corticosterone and 11-dehydrocorticosterone
were quantified by liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) (Verma et al., xxxx). Briefly, plasma samples
(150 ll) were enriched with epi-corticosterone (2.5 ng/sample) as
an internal standard and extracted using chloroform (10:1; v/v)
by briefly vortexing and discarding the upper (aqueous) layer.
The organic phase was evaporated to dryness under oxygen free
nitrogen at 60 C and resuspended in water-acetonitrile (70 ll,
70:30, v/v). The resuspended steroid sample (30 ml) was injected
onto a Waters AcquityTM UPLC system (Macclesfield, UK), chro-
matographically separated and passed into a Sciex QTRAP 5500 tri-
ple quadrupole mass spectrometer (Warrington, UK) for mass
analysis and detection. The Waters AcquityTM UPLC system was fit-
ted with an ACE ExcelC18-AR column (150  2.1 mm, 2 lm) pro-
tected by a Kinetex KrudKatcher (Phenomenex, UK). The plasma
steroids were separated at 40 C using mobile phases; 0.1% formic
acid in water (A), 0.1% formic acid in acetonitrile (B) with a flow
rate of 0.5 mL/min. Gradient elution of 30–90% B (4–6 min with a
total run time of 9 min), with epi-corticosterone, 11-
dehydrocorticosterone and corticosterone eluting at 3.50, 4.95
and 5.30 min, respectively.
Following chromatographic separation the steroids were passed
into a Turbospray ion source at 550 C, with a spray voltage of 4.5
kV and an entrance potential of 10 V. Protonated molecular ions
were subjected to collision induced dissociation for increased
specificity and the following transitions of parent-product ion were
monitored; m/z 345.1? 121.2, 90.9 at 33 and 71 V, for 11-
dehydrocorticosterone, and m/z 347.2? 91.1, 121.1 at 69 V colli-
sion energies for the isomers corticosterone and epi-
corticosterone. Data were analysed using Analyst software
v1.6.1 (SCIEX, Warrington, UK). Note that the chromatographic
retention times are consistent and distinct for the isomers corticos-Please cite this article in press as: Verma, M., et al. 11b-hydroxysteroid dehy
inflammation. Brain Behav. Immun. (2017), https://doi.org/10.1016/j.bbi.2017.terone and the non-endogenous internal standard epi-
corticosterone.
2.6. 11b-HSD enzyme activity assay
11b-HSD enzyme activity was measured by the conversion of
[3H]-11-dehydrocorticosterone (A) to [3H]-corticosterone (B)
(reductase activity) in intact peritoneal cells or by the conversion
of [3H]-corticosterone to [3H]-11-dehydrocorticosterone (dehydro-
genase activity) in tissue homogenates, as described previously
(Coutinho et al., 2016; Low et al., 1994). Briefly, 11b-
hydroxysteroid dehydrogenase activity was assayed in duplicate
at 37 C in 0.25 ml reactions containing 250 nM [3H]-
corticosterone (TRK406-250UCI, GE Life Science Healthcare, Buck-
inghamshire, UK), 2 mM NADP+ (Sigma-Aldrich, Dorset, UK) and
190 ml homogenate in C buffer (10% glycerol, 30 mM NaCl, 1 mM
EDTA, 50 mM Tris, pH7.7). Conditions were: brain, 0.5 mg protein/
ml, 2 h incubation; liver, 0.2 mg protein/ml, 20 min incubation; adi-
pose tissue, 0.2 mg protein/ml, 20 min incubation; lung, 0.5 mg
protein/ml, 40 min incubation). An 11b-oxo-reductase assay was
used to measure 11b-HSD1 activity in freshly isolated thioglycol-
late elicited peritoneal cells, lavaged 24 h after injection of 0.2 ml
10% thioglycollate, as described (Zhang et al., 2017). Peritoneal cells
were resuspended in Dulbeccos’ modification of Eagle’s medium
supplemented with 10% fetal bovine serum and seeded at 106
cells/ml in a 24 well plate. 5 nM [3H]-11-dehydrocorticosterone
(made as described (Zhang et al., 2017) was added and 200 ml of
the culturemediumwas collected 2 h later. Steroids were extracted
with ethyl acetate from reactions or from culture medium, sepa-
rated by thin layer chromatography and quantified using a phos-
phorimager and tritium screen (FLA2000, Fujifilm, London, UK)
with Aida image analysis software (Welford, UK).
2.7. RNA extraction and reverse transcription quantitative PCR
analysis
RNA was extracted and quantified as described previously
(Coutinho et al., 2016). Briefly, RNA was extracted using TRIzol
reagent (Thermo Fisher Scientific, Paisley UK) and reverse tran-
scribed using SuperScript III Reverse Transcriptase (Thermo
Fisher Scientific, Paisley UK), according to the manufacturer’s
instructions. Quantitative Real Time PCR (qRT-PCR) assays to quan-
tify specific cDNAs were designed using the Roche Universal Probe
Library (UPL) assay design system and were performed on a Light-
cycler 480 system (Roche, West Sussex, UK). Primers (Thermo
Fisher Scientific, Paisley UK) and UPL probes (Roche, West Sussex,
UK) are listed in Supplementary Table 1.
2.8. Targeted metabolomics
Specific metabolites (listed in Supplementary Table 2) in the
hippocampus were measured by BIOCRATES Life Sciences AG
(Innsbruck, Austria) according to a validated experimental proce-
dure (Ramsay et al., 2014).
2.9. Statistical analysis
Measurements of burrowing activity, mRNA, glucocorticoids,
spleen weight and leukocyte numbers were all made on one cohort
of mice (with different cohorts of mice used for each time point
after vehicle or LPS). Additional and separate cohorts of mice were
used for the targeted metabolomics and for measurement of 11b-
HSD1 activity in tissues. Statistical analyses were performed using
a Mann-Whitney test, Kruskal-Wallis test (for non-parametric
data), Student’s t-test with Welch’s correction, one way ANOVA
followed by Dunnet’s multiple comparison test, two-way ANOVAdrogenase-1 deficiency alters brain energy metabolism in acute systemic
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linear regression analysis (for parametric data), as appropriate and
as described in the figure legends. A principal component analysis
(PCA) was performed using the R package ‘‘FactoMineR” (Le et al.,
2008). Data are means ± SEM and each value represents a single
mouse. Statistical significance was set at p < .05.3. Results
3.1. Inflammatory status and hippocampal capacity for energy
metabolism is unaltered in naive Hsd11b1Del/Del mice
In the absence of an inflammatory challenge, 11b-HSD1 defi-
ciency had no effect onmarkers of peripheral or brain inflammation,
with undetectable Tnfa, Il1b and Il6 mRNA in the hippocampus of
Hsd11b1Del/Del and C57BL/6 control mice and no difference in circu-
lating neutrophil and monocyte numbers between genotypes (Sup-
plementary Fig. 4A–C). Similarly, in the hippocampus there was no
difference between naïve Hsd11b1Del/Del and C57BL/6 control mice
inmRNAs encoding a range ofmetabolic transporters and enzymes:
Slc2a1 and Slc2a3 mRNA, encoding the GLUT-1 and GLUT-3 trans-
porters responsible for glucose uptake in glial and neuronal cells,
respectively; Slc16a1, Slc16a7 and Slc16a4 mRNA encoding, respec-
tively, the MCT-1 and MCT-2 transporters responsible for lactate
uptake in glial and neuronal cells, and the MCT-4 transporter
responsible for lactate export fromglial cells; key enzymes of glycol-
ysis, the pentose phosphate pathway and mitochondrial oxidative
phosphorylation (Supplementary Fig. 4D–H). These results suggest
there is no inherent hippocampal inflammation in mice of either
genotype, nor is the capacity for energy substrate transport and
metabolism altered in the brains of naive Hsd11b1Del/Del mice. Con-
sistent with the mRNA data, there was no difference between
Hsd11b1Del/Del and C57BL/6 mice in the levels of metabolites in the
hippocampus that include intermediates in glycolysis and the tricar-
boxylic acid (TCA) cycle (Supplementary Table 2).3.2. Hsd11b1Del/Del and C57BL/6 mice show sickness behaviour
following intraperitoneal injection of LPS
Inflammation leads to marked sickness behaviour (Silverman
and Sternberg, 2012; Teeling et al., 2007; Tarr et al., 2012), which
is considered an adaptive, beneficial, and acute response to inflam-
mation to conserve energy for the activated immune system
(Silverman and Sternberg, 2012; Hart, 1988). To test whether
11b-HSD1 influences the brain response to peripheral inflamma-
tion, Hsd11b1Del1/Del1 and C57BL/6 mice were administered an
intraperitoneal injection of 100 mg/kg LPS or vehicle (0.9% saline).
This dose of LPS was chosen to limit the severity of the adverse
effects of LPS, whilst reducing burrowing activity (an assay of sick-
ness behaviour) and concomitantly inducing markers of inflamma-
tion in brains of treated animals, that normally resolves within 9 h
(Teeling et al., 2007; Czerniawski and Guzowski, 2014).
Burrowing activity was suppressed in Hsd11b1Del/Del and
C57BL/6 mice, 3 h and 6 h after LPS administration (Supplementary
Fig. 5). However, 9 h after LPS administration 2 of the 8 Hsd11b1Del/
Del mice had regained normal burrowing activity with the remain-
der showing some burrowing activity. In contrast, burrowing activ-
ity remained totally suppressed in 5 of the C57BL/6 mice at the
same time point with very little activity in all but one of the
remainder (Supplementary Fig. 5). These data potentially indicate
quicker recovery from sickness behaviour in Hsd11b1Del/Del mice
following LPS induced systemic inflammation.
Hsd11b1Del/Del mice show a normal plasma corticosterone
response to LPS administration, but have elevated levels of plasma
11-dehydrocorticosteronePlease cite this article in press as: Verma, M., et al. 11b-hydroxysteroid dehy
inflammation. Brain Behav. Immun. (2017), https://doi.org/10.1016/j.bbi.2017.As expected, plasma corticosterone levels were elevated at all
time points following LPS injection, with similar levels in
Hsd11b1Del/Del and C57BL/6 mice (Fig. 1A). There were no genotype
differences in plasma corticosterone levels in vehicle injected mice
(Fig. 1A), consistent with the normal plasma corticosterone levels
in a different line of 11b-HSD1 deficient mice on a C57BL/6 back-
ground (Carter et al., 2009). In contrast, for plasma 11-
dehydrocorticosterone levels, 2 way-ANOVA showed a significant
interaction between treatment and genotype, with markedly
higher plasma 11-dehydrocorticosterone levels in LPS-injected
Hsd11b1Del/Del mice, compared to saline-injected Hsd11b1Del/Del
mice or to LPS-injected C57BL/6 mice (Fig. 1B).
3.3. Following LPS injection, circulating leukocyte numbers are similar
between Hsd11b1Del/Del and C57BL/6 mice
Circulating neutrophils and monocytes, key mediators of
inflammation, were quantified in LPS or vehicle injected mice by
flow cytometry. The numbers of circulating neutrophils (CD45+-
CD11b+Ly6G+ cells) and pro-inflammatory Ly6Chi monocytes
(CD45+CD11b+Ly6ChiLy6G cells) were reduced 3 h after LPS injec-
tion, but with no differences between Hsd11b1Del/Del and C57BL/6
mice (Fig. 2A and B). The number of blood neutrophils recovered
by 6 h after LPS injection (Fig. 2A) and by 9 h, there were more cir-
culating neutrophils in LPS compared to vehicle-injected mice, but
with no difference between genotypes (Fig. 2A). The number of
Ly6Chi monocytes in blood remained reduced in both Hsd11b1Del/
Del and C57BL/6 mice 6 h and 9 h after LPS injection, though by 9
h the numbers of Ly6Chi monocytes had largely recovered in
C57BL/6 mice, whilst remaining reduced in Hsd11b1Del/Del mice
(Fig. 2B). There were no differences in the number of blood neu-
trophils or Ly6Chi monocytes between Hsd11b1Del/Del and C57BL/6
mice injected with vehicle (Fig. 2). Similarly, 3 h or 6 h following
either LPS or vehicle injection there was no genotype difference
in spleen weight, though spleen weight was increased by LPS in
both Hsd11b1Del/Del and C57BL/6 mice (Supplementary Fig. 6). How-
ever, by 9 h after LPS, spleen weights were lower in Hsd11b1Del/Del
mice than in C57BL/6 controls (Supplementary Fig. 6). Collectively,
these results suggest a similar peripheral inflammatory response to
this dose of LPS in Hsd11b1Del/Del and C57BL/6 mice.
3.4. Induction of pro-inflammatory cytokine mRNAs is attenuated in
the hippocampus of Hsd11b1Del/Del mice following LPS injection
LPS injection induces expression of pro-inflammatory cytokines
in the hippocampus (Teeling et al., 2007; Czerniawski and
Guzowski, 2014). To investigate the hippocampal response to LPS
in Hsd11b1Del/Del and C57BL/6 mice, levels of Tnfa, Il-1b and Il-6
mRNA were quantified. Levels of all 3 pro-inflammatory cytokine
mRNAs were elevated 3 h after LPS injection in both genotypes
(Fig. 3). However, the increase at 3 h was attenuated in
Hsd11b1Del/Del mice, compared to C57BL/6 controls (Fig. 3). Levels
of pro-inflammatory mRNAs declined rapidly and were close to
the levels in vehicle treated mice 9 h after LPS injection (Fig. 3).
These results suggest that the acute pro-inflammatory response
to LPS injection is attenuated in the hippocampus of Hsd11b1Del/
Del mice.
3.5. The hippocampus of Hsd11b1Del/Del mice shows a distinct
metabolic response to LPS
To investigate whether the attenuated hippocampal pro-
inflammatory response is associated with altered energy substrate
uptake and/or utilisation, mRNAs encoding key metabolic enzymes
and transporters were quantified in the hippocampus of
Hsd11b1Del/Del and C57BL/6 mice after LPS or vehicle injection. First,drogenase-1 deficiency alters brain energy metabolism in acute systemic
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Fig. 1. Following LPS administration, plasma corticosterone levels are similar in Hsd11b1Del/Del mice compared to controls, but 11-dehydrocorticosterone levels are elevated.
Hsd11b1Del/Del and C57BL/6 mice were injected with vehicle (0.9% saline) or 100 mg/kg LPS and euthanised 3 h, 6 h or 9 h later. (A) Plasma corticosterone and (B) 11-
dehydrocorticosterone levels were quantified by LC-MS/MS. Data are means ± SEM and were analysed by 2-way ANOVA followed by Tukey’s multiple comparisons tests: ***p
< .001, **p < .01 compared to the same genotype injected with saline, ^^^p < .001, ^^p < .01 compared to C57BL/6 mice with the same treatment; n = 6–9. Black bars, vehicle-
treated C57BL/6 mice (+/+ Saline); white bars, vehicle-treated Hsd11b1Del/Del mice (D/D Saline); horizontal hatched bars, LPS-treated C57BL/6 mice (+/+ LPS); diagonal-hatched
bars, LPS-treated Hsd11b1Del/Del mice (D/D LPS).
Fig. 2. The number of circulating neutrophils and Ly6Chi monocytes is similar in Hsd11b1Del/Del and C57BL/6 mice following LPS. Hsd11b1Del/Del and C57BL/6 mice were injected
with vehicle (0.9% saline) or 100 mg/kg LPS and euthanised 3 h, 6 h or 9 h later. (A) Neutrophils (CD45+CD11b+ Ly6G+Ly6C- cells) and (B) Ly6Chi monocytes (CD45+CD11b+
Ly6G-Ly6Chi cells) in the blood of Hsd11b1Del/Del and C57BL/6 mice 3 h, 6 h or 9 h after vehicle or LPS injection were quantified by flow cytometry. Data are means ± SEM and
were analysed by two way ANOVA followed by Fisher’s LSD tests. Significant effect of treatment (saline vs LPS): ***p < .001, **p < .01, *p < .05; n = 5–10. Black bars, vehicle-
treated C57BL/6 mice (+/+ Saline); white bars, vehicle-treated Hsd11b1Del/Del mice (D/D Saline); horizontal hatched bars, LPS-treated C57BL/6 mice (+/+ LPS); diagonal-hatched
bars, LPS-treated Hsd11b1Del/Del mice (D/D LPS).
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between experimental groups, principal component analysis was
carried out on the mRNA data at each time point. Although
principal component analysis of the 3 h and 9 h mRNA dataPlease cite this article in press as: Verma, M., et al. 11b-hydroxysteroid dehy
inflammation. Brain Behav. Immun. (2017), https://doi.org/10.1016/j.bbi.2017.showed different clusters for LPS or vehicle-injected mice, there
were no genotype differences at these time points (Supplementary
Fig. 7). However, principal component analysis of the 6 h mRNA
data (cumulative variance, 54%) showed a discrete cluster fordrogenase-1 deficiency alters brain energy metabolism in acute systemic
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Fig. 3. LPS induces expression of pro-inflammatory cytokine mRNAs in the hippocampus of Hsd11b1Del/Del and C57BL/6 mice. Hsd11b1Del/Del and C57BL/6 mice were injected
with vehicle (0.9% saline) or 100 mg/kg LPS and euthanised 3 h, 6 h or 9 h later. Levels of mRNA in the hippocampus were quantified by RT-qPCR: (A) Tnfa, (B) Il1b and (C) Il6,
(relative to Hprt and Actb mRNA, used as internal standard). For each time point, mRNA levels are expressed as fold change, relative to the levels in saline injected C57BL/6
mice at the 3 h time point (arbitrarily set to 1.0). Data are means ± SEM and were analysed by two way ANOVA followed by Tukey’s multiple comparisons tests. ANOVA
showed a significant effect of treatment at all time points for all cytokine mRNAs (***p < .001, *p < .05) and a significant interaction and effect of genotype for all cytokine
mRNAs at 3 h. Post-hoc analysis: ^p < .05 compared to C57BL/6 controls with the same treatment; n = 6–8. Black bars, vehicle-treated C57BL/6 mice (+/+ Saline); white bars,
vehicle-treated Hsd11b1Del/Del mice (D/D Saline); horizontal hatched bars, LPS-treated C57BL/6 mice (+/+ LPS); diagonal-hatched bars, LPS-treated Hsd11b1Del/Del mice (D/D
LPS).
6 M. Verma et al. / Brain, Behavior, and Immunity xxx (2017) xxx–xxxLPS-injected Hsd11b1Del/Del mice (Fig. 4). This suggests a distinct
metabolic response to acute systemic inflammation in the hip-
pocampus of Hsd11b1Del/Del mice, 6 h following LPS injection.
To explore the distinct hippocampal metabolic response in
Hsd11b1Del/Del mice 6 h after LPS injection, the same mRNA data
set was analysed at the level of individual mRNAs and a compar-
ison made between experimental groups (Fig. 5). To investigate
the functional relevance we also measured levels of specific
metabolites in the hippocampus of Hsd11b1Del/Del and C57BL/6
mice, 6 h following LPS or vehicle injection (Table 1).
Below, we focus on genes that are implicated in the Warburg
effect and in regulating flux through the tricarboxylic acid (TCA)
cycle. The effects of LPS treatment on the levels of other mRNAs,
encoding transporters (glucose and lactate) and other enzymes
involved in glycolysis or oxidative phosphorylation are described
and discussed in the text that accompanies Supplementary Fig. 8.
Increased expression of Pfkfb3 and Hk2 is associated with
aerobic glycolysis and the Warburg effect (Ando et al., 2010;Please cite this article in press as: Verma, M., et al. 11b-hydroxysteroid dehy
inflammation. Brain Behav. Immun. (2017), https://doi.org/10.1016/j.bbi.2017.Rodriguez-Prados et al., 2010; Wolf et al., 2011; De Bock et al.,
2013). Consistent with a switch to aerobic glycolysis following
LPS injection, levels of Pfkfb3 and Hk2 mRNAs were increased in
both genotypes (Fig. 5A and B). Furthermore, levels of Pfkfb3mRNA
were higher in Hsd11b1Del/Del mice than C57BL/6 controls following
LPS (Fig. 5A), though Hk2 expression did not differ between geno-
types (Fig. 5B). Expression of Eno1 is also increased in association
with aerobic glycolysis (Doherty and Cleveland, 2013). Although
Eno1 mRNA levels were unaffected by LPS, they were higher in
the hippocampus of Hsd11b1Del/Del mice than C57BL/6 controls
(Fig. 5C). Lactate dehydrogenase (LDH) plays a key role in support-
ing aerobic glycolysis. By coupling pyruvate to lactate conversion
with the oxidation of NADH, LDHA regenerates the NAD+ con-
sumed by glyceraldehyde-3-phosphate dehydrogense (GAPDH)
thereby supporting aerobic glycolysis. In contrast, LDHB preferen-
tially converts lactate to pyruvate (Brooks, 2009; Draoui and Feron,
2011) and allows mitochondrial oxidation of lactate-derived pyru-
vate (Chen et al., 2016). Expression of Ldha is associated with thedrogenase-1 deficiency alters brain energy metabolism in acute systemic
11.015
Fig. 4. Principal component analysis shows a distinct hippocampal metabolic response in Hsd11b1Del/Del mice 6 h following LPS. Hsd11b1Del/Del and C57BL/6 mice were injected
with vehicle (0.9% saline) or 100 mg/kg LPS and euthanised 6 h later. Levels of mRNA encoding metabolic transporters and enzymes were quantified relative to Hprt and Actb
mRNA levels by qPCR. Data were subject to principal component analysis to investigate differences between the experimental groups in the expression pattern of specific
genes relevant to metabolism. Individual points represent individual mice: CL (black), C57BL/6 + LPS; CS (red), C57BL/6 + saline; DL (green) Hsd11b1Del/Del + LPS; DS (blue),
Hsd11b1Del/Del + saline. A green dashed circle indicates the discrete cluster of LPS-injected Hsd11b1Del/Del mice.
M. Verma et al. / Brain, Behavior, and Immunity xxx (2017) xxx–xxx 7Warburg effect and with cancer whereas Ldhb is down-regulated in
cancer (Cui et al., 2015; Leiblich et al., 2006). Levels of Ldha mRNA
were higher in the hippocampus of Hsd11b1Del1/Del1 mice than in
C57BL/6 controls 6 h after LPS (Fig. 5D). In contrast, expression of
Ldhb, was reduced in the hippocampus of C57BL/6 mice 6 h after
LPS, but was unchanged in Hsd11b1Del1/Del1 mice (Fig. 5E). These
data support an increase in the capacity for aerobic glycolysis in
Hsd11b1Del/Del mice compared to controls, following LPS injection,
with increased flux through the GAPDH reaction supported by
higher expression of Ldha. Consistent with this hypothesis, levels
of 3-phosphoglyceraldehyde (the substrate of GAPDH), together
with dihydroxyacetone phosphate (produced in equimolar
amounts with 3-phosphoglyceraldehyde during glycolysis) were
decreased in the hippocampus of Hsd11b1Del1/Del1 mice 6 h after
LPS, but were unaffected by LPS in control mice and did not differ
between the genotypes in saline injected mice (Fig. 6A). Interest-
ingly, levels of lactate, the end product of aerobic glycolysis, were
lower in the hippocampus of Hsd11b1Del1/Del1 mice 6 h after LPS
compared to C57BL/6 or to saline injected mice (Fig. 6B), suggest-
ing increased use of lactate as a substrate for further (mitochon-
drial) metabolism during inflammation, possibly through
maintained expression of Ldhb.
We next looked at hippocampal expression of genes and
metabolites involved in mitochondrial oxidative metabolism.
Levels of CsmRNA, encoding citrate synthase and a marker of mito-
chondrial number (Hughes et al., 2014), were increased in
Hsd11b1Del1/Del1 mice compared to C57BL/6 controls, irrespective
of treatment (Fig. 5F). Levels of pyruvate + oxaloacetate, which
together feed into the citrate synthase reaction, were lower in
saline-injected Hsd11b1Del/Del mice compared to C57BL/6 (Table 1),
suggesting flux through citrate synthase may be increased in
Hsd11b1Del/Del mice. Although pyruvate + oxaloacetate levels were
reduced by LPS in control mice, they were unaffected in
Hsd11b1Del/Del mice (Table 1). Succinate dehydrogenase (SDH) is
essential in both the TCA cycle and as complex II of the electronPlease cite this article in press as: Verma, M., et al. 11b-hydroxysteroid dehy
inflammation. Brain Behav. Immun. (2017), https://doi.org/10.1016/j.bbi.2017.transport chain. It is an important sensor of ischemia: its substrate,
succinate, is an inducer of inflammation (Chouchani et al., 2014;
Tannahill et al., 2013) and accumulation of either succinate or its
product, fumarate can cause pseudo-hypoxia (Selak et al., 2005;
Isaacs et al., 2005). Moreover, SDH is the determinant of the
reserve respiratory capacity that allows cells to increase ATP under
conditions when energy demand exceeds supply (Pfleger et al.,
2015). Expression of Sdha and Sdhb (encoding the A and B subunits
of succinate dehydrogenase, respectively) showed a significant
interaction between genotype and treatment so that 6 h after LPS
injection, levels were higher in hippocampus of Hsd11b1Del1/Del1
mice compared to C57BL/6 controls (Fig. 5G and H). Consistent
with the mRNA data, two-way ANOVA showed a significant inter-
action for fumarate levels, which were increased in Hsd11b1Del/Del
compared to C57BL/6 mice following LPS injection (Fig. 6C). Succi-
nate levels were unaltered (Table 1). Collectively, these results sug-
gest an increase in mitochondrial oxidative metabolism and
reserve respiratory capacity in Hsd11b1Del/Del compared to
C57BL/6 mice, following LPS injection.3.6. Hippocampal Hsd11b1 mRNA levels are down-regulated by
systemic inflammation
Pro-inflammatory cytokines and raised plasma glucocorticoid
levels increase Hsd11b1 expression in most tissues (Chapman
et al., 2013; Morgan et al., 2014). We therefore measured levels
of Hsd11b1 mRNA in the hippocampus of LPS injected C57BL/6
mice. Steady-state Hsd11b1 mRNA levels in the hippocampus were
unaffected 3 h and 6 h after LPS injection but were reduced by 9 h
(Supplementary Fig. 9A). Moreover, we observed down-regulation
of hippocampal Hsd11b1 mRNA levels in two distinct models of
inflammation (Supplementary Fig. 9B), suggesting that down-
regulation of Hsd11b1 in the hippocampus might be a general
response to systemic inflammation.drogenase-1 deficiency alters brain energy metabolism in acute systemic
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Fig. 5. Hippocampal levels of mRNA encoding key metabolic genes suggest increased glycolysis and mitochondrial oxidation in Hsd11b1Del/Del mice, 6 h after LPS
administration. Hsd11b1Del/Del and C57BL/6 mice were injected with vehicle (0.9% saline) or 100 mg/kg LPS and euthanised 6 h later. Levels of mRNAs encoding key metabolic
transporters and enzymes in the hippocampus were quantified relative to the mean of Hprt and Actb mRNA levels by RT-qPCR. The levels of mRNA encoding (A–E) glycolytic
enzymes and (F–H) mitochondrial oxidative phosphorylation enzymes are shown. Other enzymes and transporter mRNAs are shown in Supplementary Fig. 8. Data are means
± SEM and are expressed as fold change over levels in vehicle-injected C57BL/6 mice (arbitrarily set to 1). Data were analysed by two way ANOVA which showed a significant
effect of treatment (saline vs LPS), p < .001 (A, B, G), p < .05 (F), a significant effect of genotype (C57BL/6 vs Hsd11b1Del/Del), p < .001 (C, F, H), p < .01 (D) and a significant
interaction; p < .001 (A), p < .01 (G), p < .05 (E, H). Post-hoc tests were Tukey’s (significant effect of treatment: ***p < .001, *p < .05 and of genotype: ^^^p < .001, ^^p < .01, ^p <
.05) or Fisher’s LSD (significant effect of treatment: bbp < .01 and of genotype: ap < .05); n = 6–7. Black bars, vehicle-treated C57BL/6 mice (+/+ Saline); white bars, vehicle-
treated Hsd11b1Del/Del mice (D/D Saline); horizontal hatched bars, LPS-treated C57BL/6 mice (+/+ LPS); diagonal-hatched bars, LPS-treated Hsd11b1Del/Del mice (D/D LPS).
Table 1
Hippocampal energy metabolite levels in Hsd11b1Del/Del and C57BL/6 mice 6 h post LPS or vehicle administration. Hsd11b1Del/Del (D/D) and C57BL/6 (Con) mice were injected with
vehicle (0.9% saline) or 100 mg/kg LPS and euthanised 6 h later. Hippocampal energy metabolite levels were quantified by targeted metabolomics and values are expressed relative
to the hippocampal tissue weights. Data are means ± SEM and were analysed by two way ANOVA (**p < .01, *p < .05) followed by Tukey’s multiple comparisons tests: dp < .05 (vs
same genotype with saline injection), ##p < .01, #p < .05 (vs C57BL/6 mice with the same treatment), n = 6–10.
Metabolite Saline injected (pmol/mg) LPS injected (pmol/mg) Interaction Treatment Genotype
Con D/D Con D/D
Hexose 145.7 ± 12.1 144.5 ± 13.2 154.5 ± 15.8 119.4 ± 11.6 NS NS NS
Hexose phosphate 82.8 ± 18.7 89.9 ± 14.5 92.4 ± 23.2 54.2 ± 11.90 NS NS NS
Pyruvate + Oxaloacetate 130.7 ± 13.6 77.2 ± 4.0## 96.7 ± 9.0d 95.9 ± 6.4 ** NS **
Pentose phosphate 117.1 ± 12.9 118.6 ± 4.5 133.9 ± 12.0 105.2 ± 9.5 NS NS NS
Succ acid 157.6 ± 12.9 165.3 ± 14.0 193.6 ± 13.2 170.9 ± 15.0 NS NS NS
Glutamic acid 7555.0 ± 148.2 7570.0 ± 106.0 7536.0 ± 117.0 7622.2 ± 128.8 NS NS NS
Aspartic acid 2119.5 ± 53.0 2081.0 ± 32.2 2132.0 ± 71.2 1941.3 ± 27.1# NS NS *
Arginine 69.4 ± 3.8 65.7 ± 2.0 71.4 ± 2.4 61.6 ± 2.1# NS NS *
Significant differences are highlighted in bold.
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11b-HSD1-deficient mice show an attenuated hippocampal pro-
inflammatory cytokine response to peripheral administration of a
moderate dose of LPS. This occurs despite no difference in the num-
ber of circulating inflammatory cells or in the plasma corticosterone
response to LPS. Previous studies in a different line of 11b-HSD1
deficient mice to that used here showed a greater peripheral
inflammatory response, compared to controls (Zhang and Daynes,
2007; Coutinho et al., 2012). Zhang and Daynes (2007) reported a
modest increase in the plasma cytokine response to a much higherPlease cite this article in press as: Verma, M., et al. 11b-hydroxysteroid dehy
inflammation. Brain Behav. Immun. (2017), https://doi.org/10.1016/j.bbi.2017.dose of LPS than used here, but did not measure the number of cir-
culating cells Similarly, circulating cells were not measured in our
previous study in which we showed greater recruitment of inflam-
matory cells to the serous cavities in Hsd11b1/ mice in models of
inflammation that (unlike the response to LPS) are dominated by an
early neutrophil mediated response (Coutinho et al., 2012). This
suggests that protection from a pro-inflammatory hippocampal
response to peripheral administration of LPS is mediated at a
tissue-specific level, within the brain. Local activation of GR within
the hippocampus has been implicated in priming of microglia and
potentiation of neuroinflammatory responses to LPS (Frank et al.,drogenase-1 deficiency alters brain energy metabolism in acute systemic
11.015
Fig. 6. Hippocampal levels of key metabolites are altered in Hsd11b1Del/Del and C57BL/6 mice 6 h post LPS. Hsd11b1Del/Del and C57BL/6 mice were injected with vehicle (0.9%
saline) or 100 mg/kg LPS and euthanised 6 h later. Hippocampal levels of (A) dihydroxyacetone phosphate (DHAP) + 3-phosphoglyceraldehyde (3-PGA), (B) lactate and (C)
fumarate were quantified by targeted metabolomics and values are expressed relative to the hippocampal tissue weights. Data are means ± SEM and were analysed by two
way ANOVA followed by Tukey’s multiple comparisons tests: significant effect of treatment **p < .01, *p < .05; significant effect of genotype; ^p < .05 (vs C57BL/6 mice with the
same treatment); n = 8–10. Black bars, vehicle-treated C57BL/6 mice (+/+ Saline); white bars, vehicle-treated Hsd11b1Del/Del mice (D/D Saline); horizontal hatched bars, LPS-
treated C57BL/6 mice (+/+ LPS); diagonal-hatched bars, LPS-treated Hsd11b1Del/Del mice (D/D LPS).
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involved in the effects we see here is an interesting question for
the future. We note, however, that we have not formally ruled
out blood contamination as a source of the mRNA changes we see
in hippocampus (brains were not perfused at sacrifice, to remove
blood contamination. Cytokine mRNAs are low abundance in nor-
mal brain and are the mRNAs most likely to be affected by blood
contamination (given that the blood volume in the hippocampus
is tiny and the contribution of leukocyte RNA to total hippocampal
levels of mRNAs encoding enzymes in metabolic pathways will be
insignificant). A previous study (Gabellec et al., 1995), using the
same dose and a similar time course of LPS administration as used
here, directly compared cytokine mRNAs in saline perfused and
not-perfused brains, with identical results for mRNAs encoding
IL-1a, IL-1 b and IL-1ra. This suggests it is extremely unlikely that
blood contamination could account for the increase in pro-
inflammatory cytokine levels we find in hippocampus after LPS.
The attenuated pro-inflammatory cytokine response in the hip-
pocampus ofHsd11b1Del/Delmice is associated with an alteredmeta-
bolic response that is particularly marked 6 h after injection of LPS.
This is dominated by an apparent ‘‘Warburg” effect in which
expression of key glycolytic enzymes that are typically induced
by hypoxia or in cancer, is increased. These include Pfkfb3 and Ldha,
both of which are increased by LPS to a greater extent inHsd11b1Del/
Del mice than controls. PFKFB-3 generates fructose 2,6-bis phos-
phate, a potent activator of PFK1 activity, thereby accelerating flux
through a major rate-limiting check-point of the glycolytic path-
way. Likewise, by regenerating NAD+ concomitant with lactate pro-
duction from pyruvate as the last step of glycolysis, LDHA supports
the flux through GAPDH and thus, glycolysis. An increase in flux
through glycolysis in the hippocampus of LPS injected Hsd11b1Del/
Del mice is supported by the measurement of glycolytic metabolites,
with reduced levels of 3-phosphoglyceraldehyde and dihydroxy-
acetone phosphate, that are produced downstream of PFK1 and
which feed into GAPDH. However, the metabolite measurements
only provide a snapshot at any one time, and metabolic flux analy-
sis using labelled tracers is required to confirm that glycolytic flux is
indeed increased inHsd11b1Del/Delmice following LPS. Nevertheless,
these data strongly support an increase in glycolysis in the brains of
Hsd11b1Del/Del mice in response to inflammation. Interestingly, loss
of HSD11B1 expression has been reported to enhance glycolysis in
liver cancer (Liu et al., 2016). PET imaging of 18F-FDG uptakePlease cite this article in press as: Verma, M., et al. 11b-hydroxysteroid dehy
inflammation. Brain Behav. Immun. (2017), https://doi.org/10.1016/j.bbi.2017.showed that over-expression of 11b-HSD1 in hepatocarcinoma
cells reduced glucose uptake and glycolysis in vitro, and, when
implanted in mice, reduced intrahepatic metastasis of hepatocarci-
noma, angiogenesis and tumour growth in vivo (Liu et al., 2016).
The possibility of an increased glycolytic flux is relevant to sev-
eral aspects of the phenotype of 11b-HSD1 deficiency or inhibition.
In addition to facilitating tumour growth, glycolysis plays a key
role in tissue repair following injury. Glycolysis is of crucial impor-
tance in fuelling lymphocyte activation (Pearce et al., 2013) and is
also fundamental to the process of angiogenesis and vessel branch-
ing. Loss of PFKFB3 in endothelial cells impairs angiogenesis
through reduced vessel sprouting and endothelial cell proliferation
(De Bock et al., 2013). Importantly, deficiency in, or inhibition of
11b-HSD1 is associated with increased angiogenesis in a variety
of contexts: in a sponge model of inflammatory angiogenesis, dur-
ing cutaneous wound healing, in the healing heart following coro-
nary artery ligation and in hypoxic adipose tissue during obesity
(Small et al., 2005; McSweeney et al., 2010; Michailidou et al.,
2012). Our data here suggest that 11b-HSD1-deficiency or inhibi-
tion increases the induction of Pfkfb3 expression that occurs during
the Warburg effect. The mechanism by which this occurs is
unknown, but could result from the inflammatory response seen
here in brain, and associated with tissue injury and repair.
Increased Ldha expression is also a hallmark of aerobic glycolysis.
In the normal brain, Ldha is strongly expressed in the hippocampus
(Laughton et al., 2000), and has been suggested to play a role in
synapse formation and growth (Goyal et al., 2014). Similarly, aero-
bic glycolysis may be protective in mouse models of Alzheimer’s
disease (Newington et al., 2012). On the other hand, it has been
suggested that high brain lactate levels are a hallmark of aging,
due to mitochondrial failure and consequent reliance on glycolysis
(Ross et al., 2010). However, we found no evidence of mitochon-
drial dysfunction in Hsd11b1Del/Del mice (Cs and Cox4i1 were
increased in both saline and LPS injected Hsd11b1Del/Del mice) and
indeed, hippocampal lactate levels were lower after LPS than in
control mice. Whether a greater propensity for aerobic glycolysis
contributes to the neuroprotective effect of 11b-HSD1 deficiency/
inhibition during cognitive aging (Yau et al., 2015; Yau et al.,
2001) or in mouse models of Alzheimer’s disease (Sooy et al.,
2015) remains to be determined.
Lactate represents an important metabolic fuel in brain.
Although we find evidence for increased brain glycolysis indrogenase-1 deficiency alters brain energy metabolism in acute systemic
11.015
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sponding increase in lactate levels. This raises the possibility that
lactate is used by an intracellular lactate shuttle to a greater extent
in Hsd11b1Del/Del mice than in controls after LPS. In support of this
notion, Ldhb expression is maintained in LPS injected Hsd11b1Del/Del
mice (though decreased in controls). This is consistent with a
greater level of lactate to pyruvate conversion as a fuel for mito-
chondrial oxidation (Brooks, 2009; Draoui and Feron, 2011; Chen
et al., 2016). Further support for this idea comes from the higher
level of Cs expression and lower levels of pyruvate + oxaloacetate
(substrates for the TCA cycle) in Hsd11b1Del/Del mice. Intriguingly,
we found an interaction between genotype and treatment in the
expression of the genes encoding two of the subunits of SDH/com-
plex II, with higher expression of Sdha and Sdhb in LPS injected
Hsd11b1Del/Del mice, as well as a similar interaction in levels of
fumarate, the product of SDH. Accumulation of fumarate can cause
pseudo-hypoxia by increasing HIF-1a stability (Isaacs et al., 2005;
Sullivan et al., 2013). This plausibly accounts for the increase in the
HIF-1 a target genes involved in aerobic glycolysis that also
showed the interaction between genotype and treatment in LPS
injected Hsd11b1Del/Del mice.
Whilst hypoxic signalling in vitro is not significantly altered
with 11b-HSD1 deficiency (Michailidou et al., 2012), the metabolic
alterations and gene expression changes we see in brain are all
suggestive of an increased propensity to induce HIF-1 a and thus
hypoxic response genes in the brain of Hsd11b1Del/Del mice during
inflammation. The underlying mechanisms merit further investiga-
tion. We did not find succinate to be increased but succinate accu-
mulation is a universal signature of tissue ischaemia that, during
ischaemia–reperfusion, leads to excessive mitochondrial ROS pro-
duction and ischemia–reperfusion injury, including in brain
(Chouchani et al., 2014). Increased SDH/complex II activity might
reduce ROS damage during systemic inflammation (Chouchani
et al., 2014; Guzy et al., 2008). Another mechanism by which ele-
vated SDH expression may be neuroprotective is through determi-
nation of mitochondrial reserve respiratory capacity. Reserve
capacity is a major factor in cell survival following neurotoxic
(Yadava and Nicholls, 2007) or ischemic (Pfleger et al., 2015) insult.
Interestingly in this respect, studies using carbenoxolone (a non-
selective inhibitor of 11b-HSD enzymes) and BVT-2733 (a selective
inhibitor of 11b-HSD1) found they provided neuroprotection
against ischemic brain injury in an acute setting (Beraki et al.,
2013). Whether this latter is mediated at SDH/complex II is
unknown, but our data suggest that an increase in flux through
SDH should be investigated as a potential mechanism underlying
this neuroprotective effect of 11b-HSD1 inhibition.
11-DHC levels are markedly elevated in Hsd11b1Del/Del mice
when activity of the HPA axis is increased: either during the nor-
mal diurnal rise (in saline injected mice) or in response to LPS. This
is an indication of the level of substrate normally available to 11b-
HSD1. However, the fate of corticosterone generated from 11-DHC
in C57BL/6 mice is unclear: plasma levels are similar in Hsd11b1Del/
Del and control mice. Mass spectrometry imaging of the mouse
brain has shown a reduction in the intracellular
corticosterone/11-DHC ratio with 11b-HSD1 inhibition/deficiency
including in the hippocampus, chiefly because of increased 11-
DHC levels (Cobice et al., 2013). 11b-HSD1-deficient mice are pro-
tected from the metabolic effects of corticosterone excess (Morgan
et al., 2014) as well as the adverse cognitive effects of aging or
stress – both activators of the HPA axis. During stress or in aged
mice, intrahippocampal corticosterone levels are reduced with
11b-HSD1-deficiency, despite similar plasma corticosterone levels
(Yau et al., 2015). Our data here suggest that during peripheral
inflammation, a reduction in intrahippocampal corticosterone
levels is associated with an attenuated pro-inflammatory and a
rapid metabolic response. Whether these are mediated via thePlease cite this article in press as: Verma, M., et al. 11b-hydroxysteroid dehy
inflammation. Brain Behav. Immun. (2017), https://doi.org/10.1016/j.bbi.2017.higher affinity MR or via GR is currently unclear (Yau et al.,
2011), and indeed, they may share a common mechanism or be
distinct. Nevertheless, the altered brain inflammatory response
associated with increased glycolysis, mitochondrial respiration
and induction of HIF-1 a target genes suggests this may be a neu-
roprotective mechanism during acute inflammation. Whether a
similar mechanism underlies the neuroprotective effect of 11b-H
SD1-deficiency/inhibition from accumulative damage caused by
life-time exposure to stresses that increase HPA axis activity is
an important question for the future.
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